Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had received ≥ 3 lines of therapy, six patients had received prior radiation, and seven had recurrent disease after prior autologous hematopoietic stem cell transplant (AHCT). Our cohort included one patient with HIV, two patients with hepatitis B, and two patients with CNS involvement of lymphoma. Axi-cel treatment led to significant responses with 8/10 patients achieving a complete remission at 3 months, including both patients with prior CNS involvement. The treatment was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS. One patient each with HIV and hepatitis B responded without significant toxicities. In conclusion, Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting.

中文翻译：

---

Axicabtagene ciloleucel CD19 CAR-T细胞疗法可导致10例难治性大B细胞淋巴瘤患者（包括2例HIV和病毒性肝炎）的全身和神经系统缓解率高。

Axicabtagene ciloleucel（Axi-cel）是一种CD-19嵌合抗原受体T细胞疗法，已被批准用于治疗复发/难治性弥漫性大B细胞淋巴瘤。我们在布朗克斯市的一个城市三级中心对10名获得FDA批准的DLBCL的患者进行了治疗。8例患者（80％）接受了≥3线的治疗，6例患者接受了放射治疗，7例患者接受了先前的自体造血干细胞移植（AHCT）。我们的队列包括一名艾滋病毒患者，两名乙肝患者和两名中枢神经系统淋巴瘤患者。Axi-cel治疗可导致显着缓解，其中8/10名患者在3个月时完全缓解，包括两名先前参与CNS的患者。通常，对20％≥2 CRS的患者耐受良好。艾滋病毒和乙型肝炎各一名，反应无明显毒性。总之，在实际环境中，Axi-cel在DLBCL中可产生显着的疗效并具有可控的毒性。